Home/Pipeline/OligoG (Inhaled)

OligoG (Inhaled)

Cystic Fibrosis

Phase 2Active

Key Facts

Indication
Cystic Fibrosis
Phase
Phase 2
Status
Active
Company

About Algipharma

AlgiPharma is a Norwegian clinical-stage biotech leveraging its proprietary alginate oligosaccharide (OligoG) technology to address unmet needs in respiratory diseases and infections. Its platform serves as a drug delivery vehicle for various molecule types and as a standalone therapeutic targeting mucus clearance, biofilm disruption, and antibiotic resistance. With six completed clinical trials demonstrating safety in over 175 individuals and multiple formulation routes in development, the company is positioned to advance treatments for chronic conditions like cystic fibrosis and COPD.

View full company profile

About Algipharma

AlgiPharma is a Norwegian clinical-stage biotech leveraging its proprietary alginate oligosaccharide (OligoG) technology to address unmet needs in respiratory diseases and infections. Its platform serves as a drug delivery vehicle for various molecule types and as a standalone therapeutic targeting mucus clearance, biofilm disruption, and antibiotic resistance. With six completed clinical trials demonstrating safety in over 175 individuals and multiple formulation routes in development, the company is positioned to advance treatments for chronic conditions like cystic fibrosis and COPD.

View full company profile

Other Cystic Fibrosis Drugs